Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients

Inclusion Criteria (Part A and B):

● Patient is outside of infectious period of COVID-19 defined as follows:

Patient with mild to moderate illness who are not severely immunocompromised:

At least 10 days have passed since symptoms first appeared and
At least 24 hours have passed since last fever without the use of fever-reducing medications and
Symptoms (e.g. cough, shortness of breath) have improved

Patient with severe to critical illness or who are severely immunocompromised:

At least 10 days and up to 20 days have passed since symptoms first appeared
At least 24 hours have passed since last fever without the use of fever-reducing medications and

Symptoms (e.g. cough, shortness of breath) have improved

Clinician-diagnosed MS treated or untreated with an approved DMT,
Ages 18 to 60,
EDSS 0 - 7,
Able to give informed consent,
Able to complete, or have someone help complete the patient questionnaire,
No high dose steroids, or IVIG, or PLEX use within 3 months of blood sample,
No convalescent plasma and/or polyclonal antibody treatments for COVID-19 within 3 months of blood sample collection.

Inclusion Criteria (Part B only)

COVID-19 positive patients, who received OCR within 6 months of COVID 19 infection,
EDSS 0 - 6.

Inclusion Critera (Redraws Only)

Completed standard of care COVID-19 vaccination series
On Ocrevus, glatiramer, interferon b, or not on any treatment disease-modifying treatment at the time of vaccination.

Exclusion Criteria (Part A and B):

Concurrent immunosuppressive therapy, active systemic cancer, primary or acquired immunodeficiency (i.e., CVID, HIV infection),
Active drug or alcohol abuse,
Other anti-CD20 therapy apart from OCR,
Uncontrolled diabetes mellitus,
End-organ failure (cardiac, pulmonary, renal, hepatic),
Systemic lupus erythematosus (SLE).

Exclusion Criteria (Part B only):

EDSS >6,
Active infection (e.g., hepatitis).

Exclusion Criteria (Healthy Controls Sample)

Concurrent immunosuppressive therapy, active systemic cancer, primary or acquired immunodeficiency (e.g. CVID, HIV infection),
Active ongoing drug or alcohol abuse,
Age >60 or <18,
Uncontrolled diabetes mellitus,
End-organ failure (cardiac, pulmonary, renal, hepatic),
SLE
No high dose steroids, or intravenous immunoglobulin (IVIG) or plasma exchange (PLEX) use within 3 months of blood sample collection,
No convalescent plasma and/or polyclonal antibody treatments for COVID-19 within 3 months of blood sample collection.